Thapar K, Scheithauer B W, Kovacs K, Pernicone P J, Laws E R
Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada.
Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1.
Although most pituitary tumors are well differentiated, histologically benign neoplasms, their clinical behavior is known to vary greatly. These lesions are relentlessly aggressive in some instances yet biologically indolent in others, but these prognostically relevant differences in behavior are not reflected in their histopathological appearance. As a means of identifying intrinsically aggressive pituitary tumors, we evaluated 70 pituitary adenomas and 7 primary pituitary carcinomas for their expression of the p53 gene product, a nuclear phosphoprotein whose immunohistochemical accumulation has served as an unfavorable prognostic factor for a wide range of human neoplasms. All tumors were fully classified by immunohistochemistry and electron microscopy; adenomas were further stratified on the basis of their invasion status, the latter being defined as gross operatively or radiologically apparent infiltration of dura or bone. Conclusive nuclear immunopositivity for p53 was identified in a total of 12 tumors, all being either invasive adenomas or primary pituitary carcinomas. A clear and highly significant association was evident between p53 expression and tumor behavior, as the proportion of p53-positive cases among noninvasive adenomas, invasive adenomas, and pituitary carcinomas was 0, 15.2, and 100%, respectively (chi 2 = 44.72; degrees of freedom, 2; P << 0.001). A comparison of previously reported growth fraction data with p53 expression indicated that the mean Ki-67-derived growth fraction of p53-positive tumors was significantly higher than that of p53-negative tumors (10.41 +/- 2.20 versus 2.51 +/- 0.28%) (+/- standard error of the mean, two-sample t test for independent samples, P = 0.004). There was no apparent relationship between the functional status of the tumor and p53 expression; positivity was observed among somatotroph, lactotroph, corticotroph, and clinically nonfunctioning pituitary tumors. These data indicate that p53 expression, when conclusively present in pituitary tumors, may be of some diagnostic usefulness as a marker of biologically aggressive behavior.
尽管大多数垂体肿瘤组织学上分化良好,是良性肿瘤,但其临床行为差异很大。这些病变在某些情况下具有极强的侵袭性,而在其他情况下生物学行为却较为惰性,但这些行为上与预后相关的差异并未在其组织病理学表现中体现出来。作为识别具有内在侵袭性垂体肿瘤的一种方法,我们评估了70例垂体腺瘤和7例原发性垂体癌中p53基因产物的表达情况,p53基因产物是一种核磷蛋白,其免疫组化积聚已成为多种人类肿瘤的不良预后因素。所有肿瘤均通过免疫组化和电子显微镜进行了全面分类;腺瘤根据其侵袭状态进一步分层,侵袭状态定义为手术中肉眼可见或影像学上明显的硬膜或骨质浸润。总共在12例肿瘤中确定了明确的p53核免疫阳性,所有这些肿瘤均为侵袭性腺瘤或原发性垂体癌。p53表达与肿瘤行为之间存在明显且高度显著的关联,因为在非侵袭性腺瘤、侵袭性腺瘤和垂体癌中p53阳性病例的比例分别为0、15.2%和100%(χ2 = 44.72;自由度为2;P << 0.001)。将先前报道的生长分数数据与p53表达进行比较表明,p53阳性肿瘤的平均Ki-67衍生生长分数显著高于p53阴性肿瘤(10.41 +/- 2.20对2.51 +/- 0.28%)(+/-平均标准误,独立样本双样本t检验,P = 0.004)。肿瘤的功能状态与p53表达之间没有明显关系;在生长激素瘤、催乳素瘤、促肾上腺皮质激素瘤和临床无功能垂体肿瘤中均观察到阳性。这些数据表明,当垂体肿瘤中确实存在p53表达时,它可能作为生物学侵袭性行为的标志物具有一定的诊断价值。